• Type: Oxazolidinone antibiotic
  • Dosage Forms: PO/IV
  • Common Trade Names: Zyvox
  • Bacteriostatic, so prefer another agent in bacteremia, such as ceftaroline in vancomycin resistant MRSA

Adult Dosing

  • VRE infections:
    • 600 mg PO/IV Q12H x 14-28 days
  • Pneumonia, community-acquired:
    • 600 mg PO/IV Q12H x 5 days
  • Pneumonia, hospital-acquired or ventilator-associated:
    • 600 mg PO/IV Q12H x 5 days
  • Uncomplicated skin infections:
    • 400 mg PO Q12H x 10-14 days
  • Complicated skin infections:
    • 600 mg PO/IV Q12H x 10-14 days
  • Endocarditis
    • 600 mg PO/IV Q12H x 6 weeks

Pediatric Dosing

  • >12 years old: 600mg IV/PO q12h
  • <12 years: 10mg/kg IV/PO q8-12h

Special Populations

  • Pregnancy Rating: C
  • Lactation: Infant risk cannot be ruled out
  • Renal Dosing
    • Renal impairment: no adjustment
    • Hemodialysis: give dose after HD

Hepatic dosing: no adjustment for mild-moderate impairment (Child-Pugh Class A or B)


  • Allergy to class/drug
  • Use of MAOIs, concomitantly or within past 14 days

Adverse Reactions


  • Serotonin syndrome can be caused with concomitant use with an SSRI or MAOI
  • Myelosuppression can occur after two week of use
  • Peripheral and optic neuropathy
  • Lactic acidosis
  • Clostridium difficile diarrhea
  • Liver injury
  • Seizure


  • GI upset
  • Headache
  • Fever


  • Half-life: adults- 4.7-5.1h, pediatrics- 1.5-4.1
  • Metabolism:
  • Excretion:

Mechanism of Action

Antibiotic Sensitivities[1]

Group Organism Sensitivity
Gram PositiveStrep. Group A, B, C, GS
Strep. PneumoniaeS
Viridans strepX1
Strep. anginosus gpX1
Enterococcus faecalisS
Enterococcus faeciumS
Staph. EpidermidisS
C. jeikeiumS
L. monocytogenesS
Gram NegativesN. gonorrhoeaeX1
N. meningitidisR
Moraxella catarrhalisI
H. influenzaeI
E. coliR
Klebsiella spR
E. coli/Klebsiella ESBL+R
E coli/Klebsiella KPC+R
Enterobacter sp, AmpC negR
Enterobacter sp, AmpC posR
Serratia spX1
Serratia marcescensR
Salmonella spR
Shigella spR
Proteus mirabilisX1
Proteus vulgarisR
Providencia sp.X1
Morganella sp.X1
Citrobacter freundiiX1
Citrobacter diversusX1
Citrobacter sp.X1
Aeromonas spX1
Acinetobacter sp.R
Pseudomonas aeruginosaR
Burkholderia cepaciaR
Stenotrophomonas maltophiliaR
Yersinia enterocoliticaR
Francisella tularensisR
Brucella sp.R
Legionella sp.X1
Pasteurella multocidaX1
Haemophilus ducreyiX1
Vibrio vulnificusX1
MiscChlamydophila spX2
Mycoplasm pneumoniaeR
Rickettsia spX1
Mycobacterium aviumR
Bacteroides fragilisI
Prevotella melaninogenicaX1
Clostridium difficileI
Clostridium (not difficile)X2
Fusobacterium necrophorumX1
Peptostreptococcus sp.S


  • S susceptible/sensitive (usually)
  • I intermediate (variably susceptible/resistant)
  • R resistant (or not effective clinically)
  • S+ synergistic with cell wall antibiotics
  • U sensitive for UTI only (non systemic infection)
  • X1 no data
  • X2 active in vitro, but not used clinically
  • X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
  • X4 active in vitro, but not clinically effective for strep pneumonia

See Also


  1. Sanford Guide to Antimicrobial Therapy 2014
This article is issued from Wikem. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.